Suggested Use

Nutrition Info

Description

Ultra CoQ10™ supports cellular energy production and respiration, enhances Mitochondrial electron transport and energy production, is important for overall cardiovascular and neurological health, supports healthy gum/periodontal tissue, has protective antioxidant, and is helpful in correcting CoQ10 deficiencies resulting from HMG CoA reductase inhibiting cholesterol-lowering medications.

HMG-CoA reductase inhibitors are a group of prescription drugs used to lower cholesterol, a white waxy substance that can stick to the inside of blood vessels, resulting in clogged arteries, heart disease, and strokes. These medicines work by slowing down the body’s ability to make cholesterol. Drugs in this class include atorvastatin (brand name Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pravastatin (Pravachol) simvastatin (Zocor) and cervistatin (Baycol). Collectively, they are known as "the statins." On August 8, 2001, cerivastatin (Baycol) was withdrawn from the market because of increasing reports of rare, but severe and sometimes fatal muscle damage called rhabdomyolysis.

Doctors often prescribe statins if diet, weight loss, and exercise don’t work to lower a person's cholesterol enough. Statins lower blood levels of LDL—also called "bad cholesterol"—as well decreasing blood fats called triglycerides. Statins also increase blood levels of HDL—known as "good cholesterol."

   While it is common knowledge that statins reduce cholesterol, several recent studies have highlighted new benefits. Researchers now believe that this class of medicines may lessen the risk for strokes and improve bone structure. These two effects could change how doctors prescribe these medicines and additional studies are currently underway to better understand these possible benefits.

Sources:
The Johns Hopkins Complete Home Encyclopedia of Drugs. Medletter Associates, Inc., 1998.
Drug Facts and Comparisons, Facts and Comparisons, 2001.
Pharmacotherapy: A Pathophysiologic Approach. Appleton & Lange, 1999.
White, H.D. “Pravastatin Therapy and the Risk of Stroke,” New England Journal of Medicine 343 (2000).
Wang, P.S. “HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients,” Journal of the American Medical Association 283 (2000).
Cummings, S.R."Do Statins Prevent Both Cardiovascular disease and Fracture?" Journal of the American Medical Association (2000).
Micromedex Healthcare Series. Micromedex Inc., 2001.
"Bayer Voluntarily Withdraws Baycol," U.S. Food and Drug Administration Talk Paper: http://www.fda.gov/bbs/topics/ANSWERS/2001/ANS01095.html. last accessed 8/8/01.